At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

According to the nonprofit news outlet NOTUS, at least seven studies cited in the Make America Healthy Again report released ...

Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified ...